In this respect, we previously observed that SrcDN expression and selective c-Src tyrosine-kinase inhibitors diminish cyclin D1 expression and cell cycle progression at G1-phase in breast cancer cells [24, 43, 44]. This evidence concerns the gene CCND1 and breast carcinoma.